2006
Physical activity in a cohort of HIV-positive and HIV-negative injection drug users
Smit E, Crespo C, Semba R, Jaworowicz D, Vlahov D, Ricketts E, Ramirez-Marrero F, Tang A. Physical activity in a cohort of HIV-positive and HIV-negative injection drug users. AIDS Care 2006, 18: 1040-1045. PMID: 17012097, DOI: 10.1080/09540120600580926.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-positive participantsHIV-positive injection drug usersInjection drug useHIV-negativeVigorous activityPhysical activityDrug usersDrug usePaffenbarger Physical Activity QuestionnaireRecent injection drug usersHIV-negative injection drug usersIntravenous Experience cohortActive antiretroviral therapyCohort of HIVHIV-negative participantsPhysical Activity QuestionnairePhysical activity levelsAntiretroviral therapyHIV infectionViral loadHIV treatmentActivity QuestionnaireAnthropometric measurementsEnergy expenditure
2001
Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men
Sterling T, Vlahov D, Astemborski J, Hoover D, Margolick J, Quinn T. Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. New England Journal Of Medicine 2001, 344: 720-725. PMID: 11236775, DOI: 10.1056/nejm200103083441003.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnti-HIV AgentsCD4 Lymphocyte CountDisease ProgressionDisease-Free SurvivalEligibility DeterminationFemaleHIV AntibodiesHIV InfectionsHIV-1HumansLongitudinal StudiesMalePractice Guidelines as TopicRegression AnalysisReverse Transcriptase Polymerase Chain ReactionRiskRNA, ViralSex FactorsViral LoadConceptsInitial viral loadMedian initial viral loadHIV-1 RNAViral loadLymphocyte countHuman immunodeficiency virus type 1 (HIV-1) infectionPlasma HIV-1 RNA levelsHIV-1 RNA levelsHIV-1 RNA copiesFemale injection drug usersVirus type 1 infectionHIV-1 seroconversionMedian initial CD4Risk of progressionHIV-1 infectionType 1 infectionInjection drug usersLikelihood of progressionRate of progressionAntiretroviral therapyInitial CD4Hazard ratioAntiretroviral treatmentTreatment guidelinesImmunodeficiency syndrome
2000
Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART
Carrieri M, Vlahov D, Dellamonica P, Gallais H, Lepeu G, Spire B, Obadia Y, Group T. Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. Drug And Alcohol Dependence 2000, 60: 51-54. PMID: 10821989, DOI: 10.1016/s0376-8716(00)80007-1.Peer-Reviewed Original ResearchConceptsEfficacy of HAARTDrug usersBuprenorphine substitution treatmentViral load trendsActive antiretroviral therapyFrench cohort studyHIV viral loadUse of buprenorphineInjection drug usersVirologic responseAntiretroviral therapyCohort studyBuprenorphine treatmentTreatment initiationViral loadMaintenance treatmentPotential confoundersHAARTSubstitution treatmentBuprenorphineHIVIndividual treatmentPatientsTreatmentLinear regression models
1999
Evaluating supervised haart in late-stage HIV among drug users: A preliminary report
Greenberg B, Berkman A, Thomas R, Hoos D, Finkelstein R, Astemborski J, Vlahov D. Evaluating supervised haart in late-stage HIV among drug users: A preliminary report. Journal Of Urban Health 1999, 76: 468-480. PMID: 10609596, PMCID: PMC3456696, DOI: 10.1007/bf02351504.Peer-Reviewed Original ResearchConceptsInjection drug usersResidential health care facilitiesViral load increaseViral loadDrug usersMean age 42 yearsHepatitis C virus antibodyHuman immunodeficiency virus (HIV) infectionActive antiretroviral therapyC virus antibodyTreatment-experienced patientsImmunodeficiency virus infectionAge 42 yearsHistory of dementiaLate-stage HIVHealth care facilitiesHIV/AIDSHCV seropositivityAntiretroviral therapyInitial CD4IDU populationRecord reviewSupervised therapyVirus antibodiesMedication administrationComparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load
Rompalo A, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg S, Warren D, Farzadegan H, Vlahov D, Smith D. Comparison of Clinical Manifestations of HIV Infection Among Women by Risk Group, CD4+ Cell Count, and HIV-1 Plasma Viral Load. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 20: 448-454. PMID: 10225226, DOI: 10.1097/00042560-199904150-00006.Peer-Reviewed Original ResearchConceptsHIV-1 viral loadPlasma viral loadBody mass indexHIV-1 plasma viral loadOral hairy leukoplakiaInjection drug useViral loadInjection drug usersRisk groupsHIV infectionCell countDrug useHairy leukoplakiaCells/Clinical manifestationsHeterosexual contactMedian HIV-1 viral loadPlasma HIV-1 viral loadUndetectable HIV-1 viral loadPlasma viral load levelsHIV viral loadIntravenous drug useViral load levelsPopulation of HIVPrevalence of HIVRelationship between HIV‐1 viral load and continued drug use in untreated infected injection drug users
CARRIERI M, TAMALET C, VLAHOV D, YAHI N, CHESNEY M, MOATTI J. Relationship between HIV‐1 viral load and continued drug use in untreated infected injection drug users. Addiction Biology 1999, 4: 197-202. PMID: 20575786, DOI: 10.1080/13556219971704.Peer-Reviewed Original ResearchRecent heroin injectionViral loadDrug useHeroin injectionHIV-1 plasma viral loadInfected injection drug usersHIV-1 viral loadHIV viral loadPlasma viral loadDevelopment of AIDSContinued drug useInjection drug usersLong-term progressionSelf-administered questionnaireAntiretroviral treatmentClinical stageClinical examinationMedical recordsOutpatient carePatientsDrug usersSerological assaysHospital departmentsLaboratory informationRisk practicesCell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men
Lyles C, Graham N, Astemborski J, Vlahov D, Margolick J, Saah A, Farzadegan H. Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men. European Journal Of Epidemiology 1999, 15: 99-108. PMID: 10204638, DOI: 10.1023/a:1007556327269.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBacterial InfectionsCause of DeathCD4 Lymphocyte CountCohort StudiesConfidence IntervalsDisease ProgressionFemaleFollow-Up StudiesHIV InfectionsHIV-1Homosexuality, MaleHumansImmunocompromised HostLeukocytes, MononuclearMalePredictive Value of TestsProportional Hazards ModelsRisk FactorsSubstance Abuse, IntravenousSurvival AnalysisSurvival RateViral LoadViremiaConceptsHIV-1 viral loadViral loadHomosexual menRisk groupsHIV-1Relative hazardDrug usersPeripheral blood mononuclear cellsMicroculture techniqueBlood mononuclear cellsInjection drug usersHIV-1 progressionInitial CD4Clinical progressionMononuclear cellsNegative culturesPredictive valueSurvival analysisBacterial infectionsTotal participantsAIDSProgressionInfectious unitsCells/Death
1998
Comparison of Two Measures of Human Immunodeficiency Virus (HIV) Type 1 Load in HIV Risk Groups
Lyles C, Vlahov D, Farzadegan H, Astemborski J, Margolick J, Masters B, Schroeder J, Quinn T. Comparison of Two Measures of Human Immunodeficiency Virus (HIV) Type 1 Load in HIV Risk Groups. Journal Of Clinical Microbiology 1998, 36: 3647-3652. PMID: 9817889, PMCID: PMC105256, DOI: 10.1128/jcm.36.12.3647-3652.1998.Peer-Reviewed Original ResearchConceptsInfectious viral loadInjection drug usersHIV RNA levelsHIV RNA loadViral loadRisk groupsRNA loadViral burdenHuman immunodeficiency virus type 1 (HIV-1) loadHomosexual menPlasma HIV RNA levelsMale injection drug usersFemale injection drug usersHuman immunodeficiency virus type 1Peripheral blood mononuclear cellsImmunodeficiency virus type 1RNA levelsBlood mononuclear cellsHIV risk groupViral RNA loadVirus type 1HIV loadMononuclear cellsDrug usersCell countSex differences in HIV-1 viral load and progression to AIDS
Farzadegan H, Hoover D, Astemborski J, Lyles C, Margolick J, Markham R, Quinn T, Vlahov D. Sex differences in HIV-1 viral load and progression to AIDS. The Lancet 1998, 352: 1510-1514. PMID: 9820299, DOI: 10.1016/s0140-6736(98)02372-1.Peer-Reviewed Original ResearchConceptsInjection drug usersCD4 cell countProportional hazards modelBranched-chain DNAViral loadQuantitative microcultureReverse transcriptase-PCRPlasma HIV-1 RNA measurementsCell countHIV-1 RNA measurementsUnivariate proportional hazard modelHIV-1 viral loadSame viral loadViral load associationsVisit 3 yearsHIV-1 loadViral load measurementsAntiretroviral therapyAntiretroviral treatmentBaseline visitCommunity clinicsObservational studyHIV-1Current recommendationsHigh riskPatterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline
Markham R, Wang W, Weisstein A, Wang Z, Munoz A, Templeton A, Margolick J, Vlahov D, Quinn T, Farzadegan H, Yu X. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proceedings Of The National Academy Of Sciences Of The United States Of America 1998, 95: 12568-12573. PMID: 9770526, PMCID: PMC22871, DOI: 10.1073/pnas.95.21.12568.Peer-Reviewed Original ResearchConceptsCD4 T-cell declineT-cell declineCell declineHIV-1 env sequencesFirst seropositive visitModerate disease progressionCD4 T cellsInjection drug usersLow viral loadHIV-1 evolutionLater time pointsViral loadDisease progressionT cellsDrug usersPredominant virusNonsynonymous mutationsEnv sequencesTime pointsNonprogressorsTypes of mutationsDominant variantVisitsOnly quantitative differencesViral evolutionHIV/HTLV-II Coinfection and CD4+ Cell Count Controlling for Plasma HIV Viral Load in Injection Drug Users in Baltimore
Zhang H, Flynn C, Nelson K, Chen W, Kawalski R, Vlahov D. HIV/HTLV-II Coinfection and CD4+ Cell Count Controlling for Plasma HIV Viral Load in Injection Drug Users in Baltimore. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1998, 18: 397-398. PMID: 9704951, DOI: 10.1097/00042560-199808010-00018.Peer-Reviewed Original ResearchPrognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count
Vlahov D, Graham N, Hoover D, Flynn C, Bartlett J, Margolick J, Lyles C, Nelson K, Smith D, Holmberg S, Farzadegan H. Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug Users: Plasma Viral Load and CD4+ Cell Count. JAMA 1998, 279: 35-40. PMID: 9424041, DOI: 10.1001/jama.279.1.35.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS-Related Opportunistic InfectionsBiomarkersBlack or African AmericanCD4 Lymphocyte CountDisease ProgressionFemaleHIV-1HumansMalePrognosisProportional Hazards ModelsProspective StudiesRegression AnalysisRNA, ViralSubstance Abuse, IntravenousSurvival AnalysisViral LoadConceptsInfectious disease deathsInjection drug usersPlasma viral loadViral loadDisease deathsCell countDrug usersPrognostic indicatorHuman immunodeficiency virus type 1 (HIV-1) viral loadAfrican American injection drug usersPlasma HIV-1 RNAHIV-1 viral loadInfectious diseasesClinical AIDS diagnosisLevels of CD4Kaplan-Meier analysisHIV-1 RNAPrognosis of personsPowerful prognostic informationProportional hazards modelCases of AIDSGood predictive valueCell count measurementsMedian followCohort study
1997
Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study.
Rezza G, Galai N, Pezzotti P, Vlahov D, Graham N, Viale P, Angarano G. Markers of response to zidovudine monotherapy among treated HIV seroconverters. Italian Seroconversion Study. Antiviral Therapy 1997, 2: 167-74. PMID: 11322271.Peer-Reviewed Original ResearchConceptsCD4 cell countInitiation of treatmentZidovudine monotherapyP24 antigenaemiaCell countConstitutional symptomsHIV seroconvertersRisk groupsCopies/Human immunodeficiency virus seroconvertersPlasma RNA viral loadHIV RNA copiesCD4 cell declineRNA viral loadStart of therapyMarker of responseAntigen-positive individualsAdditional predictive informationIndicator of responseStandard survival methodsTerms of progressionAntiretroviral therapyViral loadAntigen levelsDisease progressionComparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection
Shah K, Solomon L, Daniel R, Cohn S, Vlahov D. Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. Journal Of Clinical Microbiology 1997, 35: 517-519. PMID: 9003632, PMCID: PMC229616, DOI: 10.1128/jcm.35.2.517-519.1997.Peer-Reviewed Original ResearchConceptsHuman papillomavirusHybrid captureInjection drug-using womenHuman immunodeficiency virus (HIV) infectionL1 consensus primersHIV-negative womenImmunodeficiency virus infectionPap smear abnormalitiesHuman immunodeficiency virusDrug-using womenHPV prevalencePositive womenSmear abnormalitiesImmunodeficiency virusViral loadHybrid capture methodVirus infectionHigh riskComparison of PCRLow specificityConsensus primersWomenPapillomavirusPCRInfectionVitamin A levels and human immunodeficiency virus load in injection drug users.
Semba R, Farzadegan H, Vlahov D. Vitamin A levels and human immunodeficiency virus load in injection drug users. MSphere 1997, 4: 93-5. PMID: 9008289, PMCID: PMC170483, DOI: 10.1128/cdli.4.1.93-95.1997.Peer-Reviewed Original ResearchConceptsInjection drug usersInfectious viral loadHIV viral loadPlasma vitaminViral loadDrug usersHuman immunodeficiency virus (HIV) infectionPeripheral blood mononuclear cellsHuman immunodeficiency virus loadHigher vertical transmissionLow plasma vitaminImmunodeficiency virus infectionIndependent risk factorProspective cohort studyBlood mononuclear cellsEntire study populationCross-sectional studyHIV loadQuantitative microcultureCohort studyHIV infectionMononuclear cellsRisk factorsVirus loadLow vitamin
1996
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation.
Goletti D, Weissman D, Jackson R, Graham N, Vlahov D, Klein R, Munsiff S, Ortona L, Cauda R, Fauci A. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. The Journal Of Immunology 1996, 157: 1271-8. PMID: 8757635, DOI: 10.4049/jimmunol.157.3.1271.Peer-Reviewed Original ResearchConceptsHIV replicationMTB diseaseMycobacterium tuberculosisLymph node mononuclear cellsViral replicationCellular activationProtein derivative positivityPlasma viral loadAg-specific activationT cell-depleted lymphocytesPPD-negative donorsHIV diseaseHIV infectionAcute phaseViral loadImmune activationMononuclear cellsPPD positivityHealthy donorsHIV epidemicT cellsPrimary PBMCsHIV infection modelEpidemiology dataHIV